Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Lung Cancer

Volumn 75, Issue 1, 2012, Pages 102-109

  Ren, Shengxiang ^a   Zhou, Songwen ^a   Wu, Fengyin ^a   Zhang, Ling ^a   Li, Xuefei ^a   Zhang, Jie ^a   Xu, Jianfang ^a   Lv, Meijun ^a   Zhou, Caicun ^a  

^a SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Chemotherapy; DNA repair gene; ERCC1; Non small cell lung cancer; Polymorphisms

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; XRCC3 PROTEIN;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; GENOTYPE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; DNA REPAIR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; SURVIVAL RATE; TAXOIDS;

EID: 83555173540     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.05.023     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Pujol J.L., Barlesi F., Daures J.P. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006, 51:335-345.
3. Rosella R., Cobo M., Isla D., Miguel Sanchez J., Taron M., Altavilla G., et al. Applications of genomics in NSCLC. Lung Cancer 2005, 50(Suppl. 2):S33-S40.
4. Qiao Y., Spitz M.R., Shen H., Guo Z., Shete S., Hedayati M., et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002, 23:295-299.
5. Zhou C., Ren S., Zhou S., Zhang L., Su C., Zhang Z., et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 2010, 40:954-960.
6. Camps C., Sirera R., Iranzo V., Tarón M., Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 2007, 8:369-375.
7. Butkiewicz D., Rusin M., Enewold L., Shields P.G., Chorazy M., Harris C.C. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001, 22:593-597.
8. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
9. de las Peñas R., Sanchez-Ronco M., Alberola V., Taron M., Camps C., Garcia-Carbonero R., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17:668-675.
10. Matakidou A., el Galta R., Webb E.L., Rudd M.F., Bridle H., GELCAPS Consortium, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 2007, 16:2333-2340.
11. Kalikaki A., Kanaki M., Vassalou H., Souglakos J., Voutsina A., Georgoulias V., et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009, 10:118-123.
12. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 14:1797-1803.
13. Su C., Zhou S., Zhang L., Ren S., Xu J., Zhang J., et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 2010, (May). [Epub ahead of print].
14. Ren S., Zhou S., Zhang L., Xu J., Lv M., Zhang J., et al. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 2010, 28(May):1078-1083. [Epub ahead of print].
15. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004, 22:2594-2601.
16. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.
17. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004, 44:311-316.
18. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004, 91:344-354.
19. Wilson M.D., Ruttan C.C., Koop B.F., Glickman B.W. ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001, 38:209-215.
20. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998, 16:309-316.
21. Rosell R., Fossella F., Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002, 38(Suppl. 4):43-49.
22. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
23. Britten R.A., Liu D., Tessier A., Hutchison M.J., Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000, 89:453-457.
24. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
25. Krivak T.C., Darcy K.M., Tian C., Bookman M., Gallion H., Ambrosone C.B., et al. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group Study. Gynecol Oncol 2011, (April). [Epub ahead of print].
26. Park D.J., Zhang S.J., Tsao-Wei W. ERCC1 polymorphism is associated with differential ERCC1 gene expression. American association for cancer research 93th annual meeting proceedings, vol. 43 2002, 1519.
27. Yu J.J., Lee K.B., Mu C., Li Q., Abernathy T.V., Bostick-Bruton F., et al. Comparison of two human ovarian cancer cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon118 of the ERCC1 gene. Int J Oncol 2000, 16:555-560.
28. Woelfelschneider A., Popanda O., Lilla C., Linseisen J., Mayer C., Celebi O., et al. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 2008, 29:1758-1764.
29. Li F., Sun X., Sun N., Qin S., Cheng H., Feng J., et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 2010, 33:489-494.
30. Yin Z., Zhou B., He Q., Li M., Guan P., Li X., et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 2009, 9:439.
31. Matullo G., Palli D., Peluso M., Guarrera S., Carturan S., Celentano E., et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001, 22:1437-1445.
32. Fisher R.P., Morgan D.O. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994, 78:713-724.
33. Mäkelä T.P., Tassan J.P., Nigg E.A., Frutiger S., Hughes G.J., Weinberg R.A. A cyclin associated with the CDK-activating kinase MO15. Nature 1994, 371:254-257.
34. Drapkin R., Reardon J.T., Ansari A., Huang J.C., Zawel L., Ahn K., et al. Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 1994, 368:769-772.
35. Li Y., Jin G., Wang H., Liu H., Qian J., Gu S., et al. Polymorphisms of CAK genes and risk for lung cancer: a case-control study in Chinese population. Lung Cancer 2007, 58(2):171-183.
36. Chen M., Kamat A.M., Huang M., Grossman H.B., Dinney C.P., Lerner S.P., et al. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 2007, 28:2160-2165.
37. Jiao X., Ren J., Chen H., Ma J., Rao S., Huang K., et al. Ala499Val (C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with the risk of primary gallbladder adenocarcinoma-a case-control study in China. Carcinogenesis 2011, 32:496-501.
38. Dong S., Guo A.L., Chen Z.H., Wang Z., Zhang X.C., Huang Y., et al. RRM1 single nucleotide polymorphism -37C>A correlates with progression-freesurvival in NSCLC patients after gemcitabine-based chemotherapy. J Hematol Oncol 2010, 3:10.